731 people. Two years. A form of heart failure that has resisted almost every drug thrown at it. The result was positive, and narrower than the headlines suggested.
Heart failure with preserved ejection fraction, or HFpEF, is the version where the heart pumps normally but fills poorly. It causes breathlessness, swelling, and repeated hospital stays, and for decades it had almost no effective drug treatments. Obesity — particularly visceral fat around the heart — is one of its strongest drivers.
SUMMIT was a phase 3, double-blind, placebo-controlled trial. It randomized 731 adults with HFpEF and a BMI of at least 30 to weekly tirzepatide or matching placebo across 129 centres in nine countries. Tirzepatide started at 2.5mg and was escalated to the maximum tolerated dose, up to 15mg, by week 20. Median follow-up was 104 weeks.
This was a sick population. Everyone had meaningful symptom burden and reduced walking capacity at entry, and close to half had been hospitalized or treated urgently for worsening heart failure in the preceding year. That matters when reading the event counts below: these were people already close to the edge.
There were two primary endpoints, not one: time to first cardiovascular death or worsening heart failure event, and change in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at 52 weeks — a validated measure of symptoms and physical limitation.
The benefit came from hospitalizations, not deaths. The 38% relative reduction in the composite endpoint was driven almost entirely by fewer episodes of worsening heart failure requiring hospital admission or urgent intravenous treatment. Cardiovascular death on its own did not differ significantly between groups — the trial was not sized to detect that.
The symptom result was independent of the event result. A 6.9-point gain on the KCCQ scale, with a confidence interval of 3.3 to 10.6, sits above the threshold usually treated as clinically meaningful. Participants also walked 18.3 metres further in six minutes and had roughly a third lower high-sensitivity C-reactive protein, a marker of inflammation.
Something was changing in the heart itself. A cardiac imaging substudy of 106 participants, published in the Journal of the American College of Cardiology, found that tirzepatide reduced left ventricular mass by about 11 grams and paracardiac fat by about 45 millilitres versus placebo at 52 weeks. A separate Nature Medicine analysis reported lower systolic blood pressure and reduced estimated blood volume — plausible mechanisms beyond weight loss alone.
Tolerability looked like other tirzepatide trials. About 4% of the tirzepatide group stopped treatment because of gastrointestinal side effects.
In adults with obesity-related HFpEF, tirzepatide cut the risk of cardiovascular death or worsening heart failure by 38% over a median of two years — a result driven by fewer hospital admissions, not fewer deaths, alongside a meaningful gain in symptom scores.
Sources: Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. New England Journal of Medicine 2025;392:427-437 (doi:10.1056/NEJMoa2410027) · American College of Cardiology, AHA 2024 trial summary · Kramer CM, et al. JACC 2024 cardiac magnetic resonance substudy. NEJM full text · ACC summary · JACC substudy · NCT04847557.
This is not an approved use. Tirzepatide is marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea. A heart failure indication has not been granted. SUMMIT is evidence, not a label change, and prescribing decisions here belong to a cardiologist.
Two years of weekly doses is the exposure that produced this. Median follow-up was 104 weeks — roughly 104 consecutive injections. Trials report adherence as a footnote; in practice it is the whole mechanism. A missed week is invisible on its own and only shows up in aggregate.
The dose ramp is where people fall off. Escalation ran from 2.5mg to as much as 15mg over 20 weeks, and gastrointestinal symptoms cluster around each step up. Noting what you felt in the days after a dose increase gives a prescriber something specific to work with when deciding whether to hold, slow, or continue.
Read the population before applying the result. Everyone enrolled had both HFpEF and obesity with real symptom limitation. Nothing here says tirzepatide prevents heart failure in people who do not have it, and the trial says nothing about heart failure with reduced ejection fraction.
This article summarizes published clinical trial results and a professional-society trial summary for general education. It is not medical advice. Individual results vary, and any decision about starting, switching, adjusting, or stopping any GLP-1 or GIP/GLP-1 medication should be made with a prescriber.